Autism

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing…

3 years ago

First of its kind study into digital self-management support for autistic adults reveals significant improvements in anxiety levels and quality of life

Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced…

3 years ago

PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

·   Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years ·   VoxNova will be responsible…

3 years ago

Bionano Announces the Stratys™ System for OGM and VIA™ Software for Hematologic Malignancies

The Stratys™ instrument for optical genome mapping (OGM) will enable a four-fold increase in raw data generation rate compared to…

3 years ago

PaxMedica Comments on Common Stock Volatility

Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq:…

3 years ago

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL…

3 years ago

PaxMedica CEO Interviewed by The BRAIN Foundation

Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…

3 years ago

Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and a 523-gene NGS Panel for Standard Evaluation of Myeloid Cancers

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed…

3 years ago

Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease

–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of…

3 years ago

PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder

ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agencyPAX-101 internally developed supply chain entering final stagesTARRYTOWN, NY, June 14, 2023…

3 years ago